Crosstalk.

Long term outcomes from the GeparQuinto trial are out, and they’re interesting. It looked at neoadjuvant chemo including either lapatinib or trastuzumab, all followed by adjuvant trastuzumab, for HER2-positive breast cancer. Turn’s out complete pathologic response rates really do translate to better overall survival (OS, HR 0.31), and there was an OS advantage with lapatinib among hormone receptor-positive tumors. The thought is potential crosstalk among hormone receptors, HER2, and even EGFR (aka HER1) may provide better inhibition of growth signaling. |  Untch, J Clin Oncol 2018